Investigating Genetic Marker in Neurodegenerative Diseases - Companion Diagnosis in CNS
Customized Biomarker Developments For Targeted Biologics in Development For Neurodegenerative Disorders Including Alzheimer's Disease, Parkinson’s Disease, Huntington’s Disease, Schizophrenia, Autism and other CNS Disorders.
Enable Early Proof of Mechanism and Decision Making
Re-evaluate compounds that failed in clinical trials but demonstrated efficacy in a subset of patients.
Develop Diagnostics Tests for pre-screening patients to determine the optimal choice of drugs.
GDI Staff has extensive Experience In Designing CNS and Oncology Clinical Trials and Biomarker Development for Targeted Therapies
GDI can Partner with Pharmaceutical companies to develop Customized Genetic Markers for Drugs in Development
These marker can also be utilized to screen patients who will be responsive to the targeted therapy
GDI can offer Liquid Biopsy for Diagnosis, Prognosis and Drug Resistance, both De-novo and Acquired